Literature DB >> 30525089

Functional characterization of the p53 "mutome".

Eran Kotler1,2, Eran Segal1,2, Moshe Oren1.   

Abstract

Phenotypic characterization of mutations in the tumor protein p53 (TP53) gene has so far focused on a handful of relatively frequent "hotspot" mutations, accounting for only ~ 30% of cases. We expanded the scope and quantitatively measured the impact of thousands of distinct TP53 mutations in vitro and in vivo, providing insights into the connections between structure, function, evolutionary conservation and clinical impact.

Entities:  

Keywords:  deep mutational scan; gain of function (GOF); massively-parallel reporter assay (MPRA); mutant p53; phenotypic catalogue

Year:  2018        PMID： 30525089      PMCID： PMC6276857          DOI： 10.1080/23723556.2018.1511207

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  6 in total

1.  TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data.

Authors:  Liacine Bouaoun; Dmitriy Sonkin; Maude Ardin; Monica Hollstein; Graham Byrnes; Jiri Zavadil; Magali Olivier
Journal:  Hum Mutat       Date:  2016-07-08       Impact factor: 4.878

Review 2.  Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others.

Authors:  Kanaga Sabapathy; David P Lane
Journal:  Nat Rev Clin Oncol       Date:  2017-09-26       Impact factor: 66.675

Review 3.  Mutant p53 gain-of-function in cancer.

Authors:  Moshe Oren; Varda Rotter
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

Review 4.  TP53 mutations in human cancers: origins, consequences, and clinical use.

Authors:  Magali Olivier; Monica Hollstein; Pierre Hainaut
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-01       Impact factor: 10.005

5.  A Systematic p53 Mutation Library Links Differential Functional Impact to Cancer Mutation Pattern and Evolutionary Conservation.

Authors:  Eran Kotler; Odem Shani; Guy Goldfeld; Maya Lotan-Pompan; Ohad Tarcic; Anat Gershoni; Thomas A Hopf; Debora S Marks; Moshe Oren; Eran Segal
Journal:  Mol Cell       Date:  2018-07-05       Impact factor: 17.970

6.  Mutational landscape and significance across 12 major cancer types.

Authors:  Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962
  6 in total
  2 in total

1.  Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer.

Authors:  Andreea D Stuparu; Joseph R Capri; Catherine A L Meyer; Thuc M Le; Susan L Evans-Axelsson; Kyle Current; Mark Lennox; Christine E Mona; Wolfgang P Fendler; Jeremie Calais; Matthias Eiber; Magnus Dahlbom; Johannes Czernin; Caius G Radu; Katharina Lückerath; Roger Slavik
Journal:  J Nucl Med       Date:  2020-12-04       Impact factor: 10.057

2.  Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options.

Authors:  Jitka Malcikova; Sarka Pavlova; Barbara Kunt Vonkova; Lenka Radova; Karla Plevova; Jana Kotaskova; Karol Pal; Barbara Dvorackova; Marcela Zenatova; Jakub Hynst; Eva Ondrouskova; Anna Panovska; Yvona Brychtova; Kristyna Zavacka; Boris Tichy; Nikola Tom; Jiri Mayer; Michael Doubek; Sarka Pospisilova
Journal:  Blood       Date:  2021-12-23       Impact factor: 25.476
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.